Clinical Trial Update: An Efficacy and Safety Study of Epoetin Alfa (PROCRIT) Initiated at 40,000 Units Every Week Versus 80,000 Units Every Two Weeks in Anemic Patients With Cancer Receiving Chemotherapy. [Phase 2]

View source ↗

Summary

Phase 2 trial comparing two dosing schedules of epoetin alfa (PROCRIT) in cancer patients with chemotherapy-induced anemia, evaluating efficacy and safety. The …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia

Drugs mentioned

• PROCRIT (ERYTHROPOIETIN)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Anemia | Phase 2 | Status: COMPLETED